Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DX-88 · 1 trial · 1 indication
successful outcome is defined as attack resolution begun within 4 hrs after treatment and maintained for 24 hours
partial response is defined as an initial response to dosing followed by a relapse within 4 to 24 hours
| Arm | Type | Description |
|---|---|---|
| 5mg/m2 DX-88 IV | EXPERIMENTAL | 5mg/m2 DX-88 (ecallantide)administered intravenously |
| 10mg/m2 DX-88 IV | EXPERIMENTAL | 10mg/m2 DX-88(ecallantide)administered intravenously |
| 20mg/m2 DX-88 IV | EXPERIMENTAL | 20mg/m2 DX-88 (ecallantide) administered intravenously |
| 30 mg DX-88 SC | EXPERIMENTAL | 30mg DX-88(ecallantide)administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| DX-88 (ecallantide) | DRUG | solution for injection 10 mg/mL |
Inclusion Criteria: * 10 years of age or older * Documented diagnosis of HAE (Type I or II) * Patient reported to a study site no later than 4 hours following patient recognition of the onset of the attack * Willing and able to give informed consent Exclusion Criteria: * Patients with a serious i...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. | NTLA | 3 | PHASE3 | NTLA-2002, Normal Saline Administration |
| BioCryst Pharmaceuticals, Inc. | BCRX | 2 | PHASE3 | Berotralstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Donidalorsen |
| Pharvaris N.V. | PHVS | 1 | PHASE2 | deucrictibant |
| BioMarin Pharmaceutical Inc. | BMRN | 1 | PHASE1 | Dose 1 of BMN 331 |
| Astria Therapeutics, Inc. | ATXS | 1 | PHASE2 | STAR-0215 |
DX-88 is an investigational small molecule being studied for the treatment of Hereditary Angioedema (HAE), a rare genetic condition characterized by recurrent episodes of severe swelling. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
DX-88 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker symbol TAK. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Hereditary Angioedema (HAE).
DX-88 is in Phase 2 clinical development for Hereditary Angioedema (HAE). It is an investigational drug, meaning it has not been approved by regulatory agencies and is still undergoing clinical trials to assess its potential as a treatment.
DX-88 has been evaluated in one completed Phase 2 clinical trial, identified as NCT01826916, titled 'EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema.' This trial enrolled 77 participants with Hereditary Angioedema (HAE) and was a controlled study, though it was not randomized or double-blind.
DX-88 is not known to have alternative names. It is a distinct investigational small molecule being developed by Takeda Pharmaceutical Company Limited for Hereditary Angioedema (HAE). No other names for this drug have been identified in the available information.